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ABSTRACT
Objective To determine the prevalence of tuberculosis 
(TB) and HIV in 13 Zambian correctional facilities.
Methods Cross- sectional study.
Setting 13 correctional facilities in seven of the 10 
provinces in Zambia.
Participants All incarcerated individuals were eligible 
for TB and HIV screening and testing. Of the total study 
population of 9695 individuals, which represent 46.2% of 
total correctional population at the beginning of the study, 
8267 and 8160 were screened for TB and HIV, respectively.
Interventions TB and HIV screening and testing was done 
between July 2018 and February 2019.
Primary outcome measures All forms of TB, 
bacteriologically confirmed TB, drug- resistant TB, HIV.
Results Prevalence of all forms of TB and bacteriologically 
confirmed TB was 1599 (1340–1894) per 100 000 
population and 1056 (847–1301) per 100 000 population, 
respectively. Among those with bacteriologically confirmed 
TB, 4.6% (1.3%–11.4%) had drug- resistant TB.
There was no statistically significant difference in 
the prevalence of all forms of TB, bacteriologically 
confirmed TB and drug resistant TB between adults and 
juveniles: (p=0.82), (p=0.23), (p=0.68) respectively. Of 
the bacteriologically confirmed TB cases, 28.7% were 
asymptomatic. The prevalence of HIV was 14.3% (13.6%–
15.1%). The prevalence of HIV among females was 1.8 
times the prevalence of HIV among males (p=0.01).
Conclusion Compared with the study in 2011 which 
screened inmates representing 30% of the country’s 
inmate population, then the prevalence of all forms of TB 
and HIV in correctional facilities has reduced by about 
75% and 37.6%, respectively. However, compared with 
the general population, the prevalence of all forms of TB 
and HIV was 3.5 and 1.3 times higher, respectively. TB/
HIV programmes in correctional facilities need further 
strengthening to include aspects of juvenile- specific TB 
programming and gender responsive HIV programming.
INTRODUCTION
Globally, correctional facilities are dispropor-
tionately affected by tuberculosis (TB) and 
the HIV.1–3 In some correctional facilities, the 
prevalence of TB has been reported to be up 
to 100 times higher than the prevalence in 
the general population1 while the prevalence 
of HIV has been reported to be up to 23 times 
higher than the prevalence in the general 
population.3 The poor living conditions in 
correctional facilities perpetuate TB and HIV. 
While overcrowding, poor ventilation, HIV, 
poor nutrition and late case detection perpet-
uate TB, sexual violence, sharing of sharp 
objects and lack of access to condoms perpet-
uate HIV.4 5 Additionally, incarcerated people 
often come from socioeconomically disadvan-
taged backgrounds where the burden of TB 
and HIV is already high.1 3
In 2011, the prevalence of all forms of TB 
in six Zambian correctional facilities repre-
senting 30% of the total incarcerated popu-
lation was 6428 per 100 000 population, 
which was 18 times higher than the national 
estimates.6 In the same study, 0.6% of those 
with bacteriologically confirmed TB had 
rifampicin- resistant TB and the overall prev-
alence of HIV was 22.9%, which was 1.5 times 
the national prevalence.
Since the last documented prevalence 
survey, several interventions including test 
and treat for HIV, health systems strength-
ening, nutritional support, TB and HIV 
entry screening, among others, have been 
put in place to control the burden of TB 
Strengths and limitations of this study
 ► This is the only study on prevalence of tuberculosis 
(TB) and HIV in Zambian correctional facilities in the 
past 8 years.
 ► Results are generalisable to the 13 correctional fa-
cilities as a large sample was screened for TB and 
HIV.
 ► Data disaggregates can inform targeted interven-
tions to reduce the burden of both diseases.
 ► Variations in TB screening algorithms could have 
underestimated TB prevalence.
 ► Asymptomatic TB was not consistently screened for.
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and its associated risk factors in Zambia correctional 
facilities.7–10
This study aimed to determine the current prevalence 
of all forms of TB, bacteriologically confirmed TB and 




We present an analysis of cross- sectional data collected 
under programmatic conditions by the Elton John Juve-
nile Offenders’ Health (EJJOH) project. The EJJOH 
project was a health system strengthening project 
aimed at supporting provision of holistic and integrated 
health services to juvenile offenders. While the project 
primarily targeted juveniles, its support was extended to 
adults being held in the same facility with the juveniles 
so as to improve infectious disease control. The project 
screened the incarcerated population as part of its base-
line assessment.
Study setting and population
Zambia has 87 correctional facilities with a total capacity 
of 9150 incarcerated individuals.11 However, the total 
incarcerated population in Zambia was slightly over 
21 000 in 2018 and 22 823 in 2019. In 2019, almost one in 
five individuals detained were in pretrial detention.11 The 
data were collected between July 2018 and February 2019 
in 13 correctional facilities with a combined population of 
9695, representing 46.2% of the total correctional facility 
population in Zambia in 2018. The 13 correctional facili-
ties had been purposefully selected by the EJJOH project 
because they held a significant number of juveniles. The 
facilities include Lusaka Central, Kamwala Remand, 
Livingstone Central, Katombora Reformatory School, 
Nakambala Approved School, Mukobeko Medium, Ndola 
Remand, Kamfinsa State, Chingola, Insakwe Approved 
School, Chipata Central, Mongu Central and Kasama 
Central (locations shown in online supplemental figure 
1). The reformatory and approved schools hold ordered 
(convicted) juveniles (persons less than 19 years old)12; 
the other facilities are intended only for adults and 
circumstantial children13 but also hold juveniles who are 
still undergoing trial.
Across Zambia, routinely incarcerated people should 
undergo universal TB screening and HIV testing at entry 
or within 7 days of admission into correctional facilities. 
However, in some facilities, entry screening is not done 
due to various constraints. Depending on availability of 
logistics, periodic TB and HIV mass screening is carried 
out, with freedom to opt out of HIV testing but not TB 
screening and testing. TB screening is mandatory to 
increase early TB detection and treatment so as to protect 
other inmates from TB.
Study procedures
A project- specific register was used; it was a modification 
of the National Presumptive TB Register with additional 
data elements on entry point, category of individual and 
history of TB. All inmates were screened for TB; those 
who did not opt out were tested for HIV. The screening 
point was documented under one of the following cate-
gories: mass screening, entry screening from the commu-
nity or entry screening transfer from other correctional 
facility. The categories of individuals included adults 
and juveniles. Those already on anti- TB treatment at 
the time of screening were documented as TB cases and 
those on antiretroviral therapy (ART) were recorded as 
HIV positive and were not retested. Those with cough, 
fever, weight loss, nightsweats, chest pain and shortness of 
breath, irrespective of duration, were considered patients 
with presumptive TB and submitted sputum for testing 
using GeneXpert (Xpert MTB/Rif Assay; Cepheid, 
Sunnyvale, California, USA). Symptomatic individuals 
with a negative GeneXpert were referred for chest X- ray 
(CXR) depending on the clinician’s discretion. There 
were three variations to this algorithm: (1) in Lusaka 
Central, a random proportion of the incarcerated popula-
tion received CXR in addition to symptoms screening and 
those with either abnormal CXR or symptoms submitted 
sputum for GeneXpert; (2) at Ndola Remand, all except 
those already on TB treatment submitted sputum irre-
spective of symptoms; and (3) in Kabwe Medium, fluores-
cent microscopy (FM) was used for sputum examination 
instead of GeneXpert.
Alere Determine HIV- 1/2 test (AlereHIV- 1/2; Abbott, 
Chicago, Illinois, USA) was used for HIV screening and 
SD Bioline HIV- 1/2 (SD Bioline HIV- 1/2; Abbott) for 
confirmation of positive screening test, following the 
standard Zambian HIV testing algorithm. All individ-
uals received pretest and post- test HIV counselling. 
HIV- positive inmates were commenced on ART within 
1–2 days.
Data analysis
STATA Statistical Software V.14 (StataCorp, College 
Station, Texas, USA) was used for data analysis. A descrip-
tive analysis was done to determine the characteristics 
of the population screened and the prevalence of TB 
and HIV; overall prevalence and prevalence among 
subgroups were determined. The prevalence of all forms 
of TB included bacteriologically confirmed TB and clini-
cally diagnosed TB. Bacteriologically confirmed TB prev-
alence included those who had a positive GeneXpert or 
FM result, while patients already on TB treatment at time 
of screening were excluded from this analysis since data 
on the type of TB had not been collected. DR TB preva-
lence included incarcerated people with rifampicin resis-
tance on GeneXpert. Missing data were excluded from 
the analysis.
Additionally, a χ2 test was done to determine if there was 
a statistically significant difference in prevalence of TB 
and HIV between residents and new entrants into correc-
tional facilities. New entrants were defined as incarcer-
ated people whose entry point was entry screening from 
community while residents were defined as those whose 
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entry point was either mass screening or entry screening 
transfer from other correctional facility.
Patient and public involvement
The development of the research questions was intended 
to inform priority setting by the EJJOH project based on 
the disease burden in correctional facilities. The incar-
cerated population were not involved in the design of the 
project. The correctional health committees constituting 
of the incarcerated persons, correctional officers and 
healthcare workers were involved in the data collection. 
A representative of the correctional health committee at 
each correctional facility participated in the dissemina-
tion meeting on project findings.
RESULTS
Flow diagram and participant characteristics
Of the total adult and juvenile population of 9695 in the 
13 correctional facilities, 8160 (84.2%) were screened for 
HIV and 8267 (85.3%) were screened for TB (figure 1). 
Individuals not screened were 1428 (14.7%) and they 
constituted those either in court or the farms. Of those 
screened for HIV, 1170 (14.3%) were HIV positive, of 
which 816 were known positive and 354 were new posi-
tives, while 6990 (85.7%) were HIV negative. Of those 
screened for TB, 17 (0.2%) were already on treatment, 
3076 (37.3%) individuals had symptoms of TB, 5161 
(62.5%) were asymptomatic while 13 (0.2%) had missing 
data. A total of 4269 individuals had documented sputum 
results. Eighty- seven bacteriologically confirmed TB cases 
were reported including 25 (28.7%) asymptomatic indi-
viduals and 62 (71.3%) symptomatic individuals. A total 
of 132 TB cases were identified including 87 (65.9%) 
bacteriologically confirmed TB cases, 28 (21.2%) clini-
cally diagnosed TB cases and the 17 (12.9%) that were 
already on TB treatment at the time of screening.
Of those screened, 7805 (94.41%) were adults and 462 
(5.58%) were juveniles (table 1). The overall median age 
(IQR) of the participants was 32 years (IQR 10–93); the 
median ages for the adults and juveniles were 33 (IQR 
19–93) and 17 (IQR 10–18), respectively. The males were 
8167 (98.79%), participants with a history of TB were 467 
(5.65%), resident inmates were 7767 (93.95%) while new 
entrants were 497 (6.01%).
Prevalence of all forms of TB and bacteriologically confirmed 
TB
The overall prevalence of all forms of TB was 1598 (1339–
1892) per 100 000 population while the overall prevalence 
of bacteriologically confirmed TB was 1056 (844–1301) 
per 100 000 population (table 2). There was no statistically 
significant difference in the prevalence of both all forms 
of TB and bacteriologically confirmed TB between males 
and females, (p=0.51) and (p=1.00), respectively. It was 
Figure 1 Flow diagram of tuberculosis (TB) screening and diagnosis. *All symptomatic patients submitted sputum; however, 
some correctional facilities only documented results of patients with positive results.
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the same for adults and juveniles, (p=0.82) and (p=0.23), 
respectively, and the new entrants and residents, (p=0.25) 
and (p=0.21), respectively.
Prevalence of DR TB
Among the bacteriologically confirmed TB cases, the 
overall prevalence of DR TB was 4.6% (1.3%–11.4%) 
(table 3). There was no statistically significant differ-
ence in prevalence of DR TB between males and females 
(p=0.95), between adults and juveniles (p=0.68), between 
those with and those without history of TB (p=0.72) and 
between the new entrants and residents (p=0.26).
Prevalence of HIV
The overall HIV prevalence was 14.3% (13.6%–15.1%) 
(table 4). The prevalence of HIV among males was 14.1% 
(13.4%–14.9%) and among females 25.8% (16.6%–
35.1%) (p=0.01). The prevalence of HIV among adults 
and juveniles was 15.0% (14.1%–15.7%) and 3.9% 
(2.3%–6.2%) (p<0.01), respectively. There was no statisti-
cally significant difference in prevalence of HIV between 
residents and new entrants (p=0.05).
DISCUSSION
Statement of principal findings
This study found that in Zambian correctional facili-
ties, the prevalence of all forms of TB, bacteriologically 
confirmed TB and DR TB was 3.5 times higher,14 1.7 
times higher14 and 3.5 times higher,15 respectively, than 
the respective prevalence in the general population. 
Additionally, the overall prevalence of HIV was 1.3 times 
higher than the prevalence in the general population,16 
and the prevalence of HIV among females was 1.8 times 
higher than the prevalence of HIV among males within 
Table 1 Characteristics of population screened
Variable Participants (n=8267)
Category of individual, n (%)
  Adults 7805 (94.41)
  Juveniles 462 (5.58)
Median age (IQR)
  Overall 32 (10–93)
  Adults (≥19 years) 33 (19–93)
  Juveniles (<19 years) 17 (10–18)
Sex, n (%)
  Male 8167 (98.79)
  Female 89 (1.08)
  Missing 11 (0.13)
History of TB, n (%)
  Yes 467 (5.65)
  No 7786 (94.18)
  Missing 14 (0.17)
Type of screening visit, n (%)
  Mass screening 7602 (91.92)
  Entry screening other correctional facility 165 (2.00)
  Entry screening community 497 (6.01)
  Missing 3 (0.04)
TB, tuberculosis.
Table 2 Prevalence of all forms of TB and bacteriologically confirmed TB
Cases/participants 
(n/N)
Prevalence of all 
forms of TB per 





confirmed TB per 
100 000 (CI) P value
Overall 132/8254* 1599 (1340 to 1894) 87/8237*† 1056 (847 to 1301)
Sex
  Male 129/8154 1582 (1322 to 1877) 0.60 84/8137 1032 (824 to 1276) 0.79
  Female 1/89 1124 (28 to 6102) 1/89 1124 (28 to 6102)
  Missing gender 2/11   2/11
Category of individual
  Adult (≥19 years) 124/7792 1591 (1325 to 1894) 0.82 79/7775 1016 (805 to 1265) 0.23
  Juvenile (<19 years) 8/462 1732 (750 to 3383) 8/462 1732 (750 to 3383)
Entry point*‡
  Residents 121/7757 1560 (1296 to 1861) 0.25 79/7740 1020 (809 to 1270) 0.21
  New entrants 11/494 2227 (1117 to 3949) 8/494 1619 (702 to 3166)
Residents include those screened through mass screening and those under entry screening as a transfer from other correctional facility. New entrants 
include those screened under entry screening from the community (police cells).
*Thirteen participants had missing values on TB.
†Seventeen participants were already on TB treatment, bacteriological status unknown.
‡Three participants had missing values on entry point.
TB, tuberculosis.
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correctional facilities. Of the bacteriologically confirmed 
TB cases, 28.7% were asymptomatic.
Study findings in relation to other studies
It is noteworthy that there is no statistically significant 
difference in prevalence of all forms of TB and bacterio-
logically confirmed TB between juveniles and adults and 
that in fact the point estimates for TB in juveniles were 
higher; generally older adults have a higher TB burden 
than adolescents.17 18 This suggests that the dispro-
portionate access to TB services and health services in 
general among juveniles in Zambian correctional facil-
ities reported between 2009 and 2010 has persisted.19 
Another significant contrast relative to the general popu-
lation is the absence of a statistically significant difference 
in prevalence of bacteriologically confirmed TB between 
males and females.14 This could be due to absence of 
gender- related differences in exposure to risk factors for 
TB infection and disease but could also be due to the 
small sample size and very wide CIs among females.
In comparison to the 2010–2011 study, the prevalence 
of all forms of TB has reduced by about 75% while the 
prevalence of bacteriologically confirmed TB has reduced 
by 50%.6 The reduction in prevalence of all forms of TB 
and bacteriologically confirmed TB could be a result 
of the TB interventions being implemented within the 
Zambian correctional facilities since 2011. This explana-
tion is supported by findings from an observational and 
modelling study done in Brazil: entry screening, active 
screening for TB among inmates, TB preventive therapy 
and annual mass screening independently reduce the 
incidence of TB in correctional facilities by 10.3%, 
35%, 23.5% and 47.5%, respectively, after a period of 10 
years and a combination of these interventions reduces 
the TB incidence by 79.2% after a period of 10 years.20 
However, it is worth mentioning that though the previous 
study used a more sensitive algorithm involving X- ray 
and culture21 22 for all inmates, the reduction is so large 
that it cannot simply be explained by use of different 
algorithms. Other countries in sub- Saharan Africa with 
results involving multiple correctional facilities report TB 
prevalence ranging from 457 to 888 per 100 000 popula-
tion.23–25 However, a direct comparison to the prevalence 
reported in the other countries can not be done due to 
differences in definitions of TB used and differences in 
prevalence in the general population.
The prevalence of DR TB among people with no 
history of TB is similar to the prevalence among people 
with history of TB, suggesting significant transmis-
sion of DR TB either in correctional facilities or in the 




Prevalence of DR 
TB % (CI) P value
Overall 4/87 4.6 (1.3 to 11.4)
Sex
  Male 4/84 4.8 (1.3 to 11.7) 0.95
  Female 0/1 0 (0 to 97.5)*
  Missing 0/2
Category of individual
  Adults 
(≥19 years)
4/79 5.1 (1.4 to 12.5) 0.68
  Juveniles 
(<19 years)
0/8 0 (0 to 3.7)*
History of TB
  No 3/64 4.7 (1.0 to 13.1) 0.72
  Yes 1/23 4.3 (0.1 to 21.9)
Entry point
  Residents 3/76 3.8 (0.8 to 10.7) 0.26
  New 
entrants
1/8 12.5 (0.3 to 52.7)
Residents include those screened through mass screening 
and those under entry screening as a transfer from other 
correctional facility. New incarcerated individuals include 
those screened under entry screening from the community 
(police cells).
*One sided, 97.5% CI.
DR TB, drug- resistant tuberculosis.




Prevalence of HIV 
% (CI) P value
Overall 1170/8160* 14.3 (13.6 to 15.1)
Sex
  Male 1139/8061 14.1 (13.4 to 14.9) 0.00
  Female 23/89 25.8 (17.4 to 36.2)




  Adults 
(≥19 years)
1153/7727 15.0 (14.1 to 15.7) 0.00
  Juveniles 
(<19 years)
17/433 3.9 (2.3 to 6.2)
Entry point*†
  Residents 1118/7699 14.5 (13.7 to 15.3) 0.06
  New 
entrants
52/460 11.3 (8.6 to 14.6)
Residents include those screened through mass screening 
and those under entry screening as a transfer from other 
correctional facility. New incarcerated individuals include 
those screened under entry screening from the community 
(police cells).
*One hundred and seven participants either opted out of 
HIV testing or had missing data.
†Three3 participants had missing entry point, 2 of which 
also had missing HIV status.
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communities where the incarcerated people come from, 
or both. Strengthening TB infection control can reduce 
transmission of DR TB.26 In comparison to the 2010–2011 
study, the prevalence of DR TB has increased by 667%.6 
The increasing trend of DR TB in the Zambian correc-
tional facility setting is also seen at the global and national 
levels.27 The prevalence of DR TB in this study can not 
be directly compared with other correctional facility 
settings since the forms of drug resistance reported are 
different.28–30
Similar to the national picture, the prevalence of HIV 
was higher among adults than juveniles and was higher 
among females than males.16 However, the prevalence of 
HIV in women relative to the prevalence of HIV in men 
is much higher in the incarcerated population than the 
general population because women with HIV risk factors 
like sex worker status, intimate partner violence and drug 
and substance abuse are over- represented in this popula-
tion.31 Additionally, women are exposed to sexual abuse 
while in custody and they have more access barriers to HIV 
prevention, testing and treatment services compared with 
men.32 Despite the very high rates of HIV in this group, 
relative to the study done by Simooya et al in 1999, which 
showed a prevalence of 33% in females, the prevalence of 
HIV has reduced.33 There has been a 37.6% reduction in 
overall prevalence of HIV since the study in 2010–2011.6 
The reduction in prevalence of HIV in correctional facil-
ities is attributable to the reduction of HIV prevalence in 
the general population,16 the implementation of test and 
treat across Zambia,34 entry HIV testing and treatment6 
and use of correctional health committees to strengthen 
TB/HIV service delivery at facility level.9 Among African 
countries with studies involving several correctional facil-
ities, Zambia’s prevalence is lower than South Africa’s25 
but higher than Burkina Faso and Uganda.
The difference in prevalence of TB and HIV between 
residents and new entrants into correctional facilities 
was not statistically significant. This is possibly due to 
the following reasons: (a) individuals entering correc-
tional facilities come from socioeconomically disadvan-
taged backgrounds where prevalence of TB and HIV is 
already high1; (b) there are high rates of recidivism35; and 
(c) detainees spend long periods in police cells, which 
have similar conditions to the correctional facilities.36 37 
However, the small sample size and wide CIs especially 
for the new entrants are a limiting factor for drawing any 
inferences from this comparison. This finding highlights 
the contribution of imported TB and HIV cases to the 
burden of disease in correctional facilities and under-
scores the importance of entry screening within this 
setting.
Strengths and limitations
This study provides the most recent evidence on prev-
alence of TB and HIV in Zambian correctional facili-
ties. The results of this study are generalisable to the 
13 correctional facilities, as a large sample representing 
85% and 84% of the 13 correctional facility population 
was screened for TB and HIV, respectively. By virtue of 
the data being disaggregated, it provides an opportunity 
for targeting of interventions that can reduce the burden 
of both diseases. However, there were variations in the 
strength of screening algorithms for TB, hence the prev-
alence of TB could have been underestimated in some 
correctional facilities. That said, among all forms of TB 
cases, it is possible that some of the clinically diagnosed 
TB cases might not be true TB cases as there are other 
differential causes of CXR abnormalities that mimic TB. 
Inmates in court or on the farms were not screened for 
TB which could have introduced bias during data collec-
tion. Additionally, asymptomatic TB was not consistently 
screened for.
CONCLUSION
Despite significant progress over the last decade in 
controlling TB and HIV in Zambian correctional facili-
ties, these continue to be disproportionately affected 
by both diseases. TB/HIV programmes in correctional 
facilities need further strengthening to include aspects 
of juvenile- specific TB programming, gender respon-
sive HIV programming and holistic integrated service 
delivery as TB and HIV are not exclusive health concerns 
of incarcerated individuals. Additionally, there is a need 
to consider use of more sensitive algorithms that include 
CXR to minimise the risk of missing asymptomatic TB 
cases. Additional studies are required to determine the 
true prevalence of asymptomatic TB in correctional facili-
ties, to better understand the reason for high HIV burden 
among females in correctional facilities and to determine 
the prevalence of TB and HIV using a sample whose 
results can be generalised to all the correctional facilities 
in Zambia.
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